Your browser doesn't support javascript.
loading
Efficacy of azithromycin in the treatment of cutaneous leishmaniasis
Prata, Aluízio; Silva-Vergara, Mario Léon; Costa, Laércio; Rocha, Ademir; Krolewiecki, Alejandro; Silva, Jaime Costa; Paula, Edvá Vieira de; Pimenta Junior, Fabiano Geraldo; Giraldo, Luiz Eduardo Ramirez.
  • Prata, Aluízio; Faculdade de Medicina do Triângulo Mineiro. Department of Infectious and Parasitic Diseases. Uberaba. BR
  • Silva-Vergara, Mario Léon; Faculdade de Medicina do Triângulo Mineiro. Department of Infectious and Parasitic Diseases. Uberaba. BR
  • Costa, Laércio; Municipal Polyclinic of Araçuaí. BR
  • Rocha, Ademir; Universidade Federal de Uberlândia. Department of Pathology. Uberlândia. BR
  • Krolewiecki, Alejandro; Fundacion Huesped. Buenos Aires. AR
  • Silva, Jaime Costa; Ministério da Saúde. Fundação Nacional de Saúde. Belo Horizonte. BR
  • Paula, Edvá Vieira de; Ministério da Saúde. Fundação Nacional de Saúde. Belo Horizonte. BR
  • Pimenta Junior, Fabiano Geraldo; Ministério da Saúde. Fundação Nacional de Saúde. Belo Horizonte. BR
  • Giraldo, Luiz Eduardo Ramirez; Faculdade de Medicina do Triângulo Mineiro. Department of Infectious and Parasitic Diseases. Uberaba. BR
Rev. Soc. Bras. Med. Trop ; 36(1): 65-69, jan.-fev. 2003. tab
Article in English | LILACS | ID: lil-332890
ABSTRACT
The present open pilot study was conducted to assess the efficacy of azithromycin for the treatment of patients with cutaneous leishmaniasis in Araçuaí and Varzelândia, MG. Twenty-four patients with less of six months of disease evolution were treated after clinical examination, Montenegro test and a biopsy. The treatment schemes consisted of oral doses of 500 mg per day for 3, 5 and 10 days and of 1000 mg for two days. A clinical control was performed monthly and treatment cycles were repeated when necessary until full reepithelialization of the lesions. On the occasion of the final evaluation, 20 patients had completed the study and 17 of them (85 percent) were cured. The time to obtain a cure was 60 days ifor 6 (30 percent) patients, 90 days for 7 (35 percent), and 120 for 4 (20 percent). The three patients with treatment failure received a pentavalent antimonial for 20 days. No adverse reactions to the medication were observed and a 14 month follow-up did not show recurrence in any patient. These results suggest that azithromycin can be a good therapeutic option for the treatment of cutaneous leishmaniasis caused by Leishmania Viannia brasiliensis
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Leishmaniasis, Cutaneous / Azithromycin / Anti-Bacterial Agents Type of study: Evaluation studies / Observational study / Prognostic study Limits: Animals / Female / Humans / Male Language: English Journal: Rev. Soc. Bras. Med. Trop Journal subject: Tropical Medicine Year: 2003 Type: Article Affiliation country: Argentina / Brazil Institution/Affiliation country: Faculdade de Medicina do Triângulo Mineiro/BR / Fundacion Huesped/AR / Ministério da Saúde/BR / Municipal Polyclinic of Araçuaí/BR / Universidade Federal de Uberlândia/BR

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Leishmaniasis, Cutaneous / Azithromycin / Anti-Bacterial Agents Type of study: Evaluation studies / Observational study / Prognostic study Limits: Animals / Female / Humans / Male Language: English Journal: Rev. Soc. Bras. Med. Trop Journal subject: Tropical Medicine Year: 2003 Type: Article Affiliation country: Argentina / Brazil Institution/Affiliation country: Faculdade de Medicina do Triângulo Mineiro/BR / Fundacion Huesped/AR / Ministério da Saúde/BR / Municipal Polyclinic of Araçuaí/BR / Universidade Federal de Uberlândia/BR